Tiziana Life Sciences Ltd Asset Resilience Ratio
Tiziana Life Sciences Ltd asset resilience ratio. Tiziana Life Sciences Ltd (TLSA) has an Asset Resilience Ratio of 0.00% as of June 2019. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Tiziana Life Sciences Ltd liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Tiziana Life Sciences Ltd (2000–2018)
Asset resilience ratio of Tiziana Life Sciences Ltd from 2000 to 2018. This chart shows how Tiziana Life Sciences Ltd's Asset Resilience Ratio has changed over time. Read how much debt does Tiziana Life Sciences Ltd carry for a breakdown of total debt and financial obligations.
Liquid Assets Composition Over Time
This chart breaks down Tiziana Life Sciences Ltd's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see total assets of Tiziana Life Sciences Ltd.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Tiziana Life Sciences Ltd maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Tiziana Life Sciences Ltd Industry Peers by Asset Resilience Ratio
Compare Tiziana Life Sciences Ltd's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
Madrigal Pharmaceuticals Inc
NASDAQ:MDGL |
Biotechnology | 62.31% |
|
Beijing Wantai Biological Pharmacy Enterprise Co Ltd
SHG:603392 |
Biotechnology | 10.35% |
|
Xiamen Amoytop Biotech Co Ltd
SHG:688278 |
Biotechnology | 4.69% |
|
SOLENO THERAPEUT. DL-001
F:6XC |
Biotechnology | 41.74% |
|
89bio Inc
NASDAQ:ETNB |
Biotechnology | 71.60% |
|
LegoChem Biosciences Inc
KQ:141080 |
Biotechnology | 55.88% |
|
DNA Link Inc
KQ:127120 |
Biotechnology | 0.00% |
Tiziana Life Sciences Ltd Asset Resilience Ratio by Year (2000–2018)
Tiziana Life Sciences Ltd asset resilience ratio by year from 2000 to 2018. The table below shows the annual Asset Resilience Ratio data for Tiziana Life Sciences Ltd.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2018-12-31 | 0.00% | $0.00 | $5.45 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $9.25 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $2.46 Million | -- |
| 2002-12-31 | 20.90% | $536.00K | $2.56 Million | +16.46pp |
| 2000-12-31 | 4.44% | $200.00K | $4.50 Million | -- |
About Tiziana Life Sciences Ltd
Tiziana Life Sciences Ltd, a biotechnology company, engages in the development of transformative therapies for neurodegenerative and lung diseases in the United States. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for use in the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes… Read more